Search Results - Therapeutic

34 Results Sort By:
Organ Preconditioning with Mitochondrial Elongating Agents M1/Mdivi1 in Transplantation
M1/Mdivi1 as a novel treatment to reduce immunogenicity in organ transplantationTechnology: Addition of M1 and Mdivi1 drugs in organ preservation solutions can reduce the immunogenicity of the donor organ’s microvascular endothelial cells (ECs), thereby promoting allograft immune tolerance. Inventors at MUSC have found that the use of M1 (a m...
Published: 3/19/2018   |   Inventor(s): Satish Nadig, Carl Atkinson, Danh Tran
Keywords(s):  
Category(s): Therapeutic
Total Body Irradiation Using Pre-Existing Dose Dynamic Fields
Technology: TA library of pre-commissioned dose dynamic fields offers a simple method for delivery of total body irradiation (TBI) given in preparation for transplant. This simple technique is available for any VMAT-capable machine, regardless of the treatment room size or span of the MLCs, yet does not require complex planning or patient-specific ...
Published: 10/9/2017   |   Inventor(s): Nicholas Koch
Keywords(s):  
Category(s): Therapeutic
Cyclic Peptide Inhibitors of Lysine-Specific Demethylase 1- Sickle Cell Disease
Cyclic Peptide Inhibitors of Lysine-Specific Demethylase 1 (LSD1) for Sickle Cell Disease Technology: Researchers at MUSC have used a ligand-based approach to design and synthesize a series of cyclic peptides that are effective inhibitors of LSD1, and have greater stability to proteolytic degradation than their linear homologues. For example, cycli...
Published: 9/13/2017   |   Inventor(s):  
Keywords(s):  
Category(s): Therapeutic
Mitochondrial targeted HDAC inhibitors for the treatment of heart failure and related diseases and disorders (MitoDACs)
Mitochondrial targeted HDAC inhibitors for the treatment of heart failure and related diseases and disorders (MitoDACs)Technology: Researchers at MUSC have discovered HDAC1 is present in the adult cardiac myocyte mitochondria. A series of HDAC1 inhibitors that target mitochondria have been made (MitoDACs). One of the analog, LL-66, localizes to the...
Published: 8/22/2017   |   Inventor(s): Donald Menick, Chung-jen (james) Chou, Daniel Herr, Xiaoyang Li
Keywords(s):  
Category(s): Therapeutic
Pharmaceuticaly Modified T cells for Adoptive Cell Therapy Against Cancer
Inventors have found that treatment of tumor-reactive human T cells with drugs that co-modulate β-catenin and PI3Kδ enhances their antitumor capacity, especially their ability to exert a long-term immune response against cancer. Th17 cells inhibited of both pathways expressed less RORγt, which, in turn, reduced their ability to sec...
Published: 7/10/2017   |   Inventor(s): Chrystal Paulos, Kinga Majchrzak, Jacob Bowers
Keywords(s):  
Category(s): Therapeutic
Antifibrotic effects of oxetanyl sulfoxides
Technology: Currently, there are only two approved therapies for Idiopathic Pulmonary Fibrosis (IPF), pirfenidone and nintedanib, which are minimally effective at slowing the disease. These treatments are not effective at all in halting or reversing the progression of IPF. Therefore, there remains a great need for more effective therapies. Research...
Published: 6/14/2017   |   Inventor(s): Carol Feghali-bostwick, Peter Wipf
Keywords(s):  
Category(s): Therapeutic
Delivery of chemotherapeutics to brain tumors
Technology: Brain cancer is a life-threatening disease with a poor prognosis. This includes Glioblastoma Multiform (GBM), which has a standard treatment of surgical resection, radiation therapy and concurrent chemotherapy with temozolomide (TMZ). The median survival is 14 months because surgeons are unable to completely remove GBM, radiation does n...
Published: 5/18/2017   |   Inventor(s): Ann-marie Broome, Suraj Dixit, Amy-lee Bredlau
Keywords(s):  
Category(s): Therapeutic
CD38 mediated metabolic axis in anti-tumor T cell immunotherapy
Technology: MUSC researchers have identified T cells with reduced surface expression of NADase CD38 exhibited intrinsically higher NAD+ levels, enhanced oxidative phosphorylation, higher glutaminolysis and altered mitochondrial dynamics that vastly improved tumor control. Inventors identified combining the culture conditions of Th17ILβ+TGF&bet...
Published: 5/12/2017   |   Inventor(s): Shikhar Mehrotra, Shilpak Chatterjee
Keywords(s):  
Category(s): Therapeutic
Improving Tumor Suppression Effects of Cisplatin Utilizing a HPV Derived Peptide for Head and Neck Cancers
Technology: Inventors found that human papillomavirus (HPV) activates a specific protein called E2F5 to improve cell death in HPV (+) head and neck squamous cell carcinoma (HNSCC) cells and tumors in culture and in animals. Using molecular, pharmacologic and genetic tools, the inventors have shown that HPV early protein 7 (E7) enhances ceramide-med...
Published: 4/11/2017   |   Inventor(s): Besim Ogretmen, Raquelia Thomas, Natalia Oleinik
Keywords(s):  
Category(s): Therapeutic
LSD1 Protein Inhibitors as Fetal Hemoglobin Inducers for Sickle Cell Disease
Researchers at MUSC have identified several potential inhibitors of lysine-specific demethylase 1 (LSD1) utilizing a virtual screen, and found compounds that fit the LSD1 active site in silico. Researchers have synthesized these molecules and evaluated them as LSD1 inhibitors, and several compounds inhibit the enzyme with Ki values in the mid-to up...
Published: 4/4/2017   |   Inventor(s): Patrick Woster, Craig Kutz
Keywords(s):  
Category(s): Therapeutic
1 2 3 4 
© 2018. All Rights Reserved. Powered by Inteum